Expert consensus on clinical management of metabolic bone disease of prematurity (2021).
10.7499/j.issn.1008-8830.2105152
- Author:
Chang YAN-MEI
1
;
Lin XIN-ZHU
;
Zhang RONG
;
Liu XI-HONG
;
Tong XIAO-MEI
1
;
Chen PING-YANG
;
Feng ZHI-CHUN
Author Information
1. Department of Pediatrics, Peking University Third Hospital, Beijing 100191 China.
- Collective Name:Nutritional Committee of Neonatology Branch of Chinese Medical Doctor Association;Neonatal Nutrition and Health Management Group, Professional Committee of Child Health, Chinese Medical Doctor Association;Editorial Committee of Chinese Journal of Contemporary Pediatrics.
- Publication Type:Journal Article
- Keywords:
Bone mineralization and growth;
Expert consensus;
Metabolic bone disease;
Osteopenia;
Preterm infant
- MeSH:
Aftercare;
Bone Diseases, Metabolic/therapy*;
Consensus;
Humans;
Infant, Newborn;
Infant, Premature;
Patient Discharge
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(8):761-772
- CountryChina
- Language:English
-
Abstract:
Metabolic bone disease of prematurity (MBDP) is a systemic bone disease with a reduction in bone mineral content due to disorder of calcium and phosphorus metabolism. There is still a lack of in-depth research and systematic understanding of MBDP in China, and there are many irregularities in clinical management of this disease. Based on relevant studies in China and overseas, Grading of Recommendations Assessment, Development and Evaluation was used to develop the expert consensus on the clinical management of MBDP, which provides recommendations from the following five aspects: high-risk factors, screening/diagnosis, prevention, treatment, and post-discharge follow-up of MBDP, so as to provide relevant practitioners with recommendations on the clinical management of MBDP to reduce the incidence rate of MBDP and improve its short- and long-term prognosis.
